Fig. 3

Loss of Fbxo22 impairs MLL-AF9-induced mouse AML development during serial transplantation. A Representative images (left) of serial colonies and colony numbers (middle and right, n = 3) formed by GFP⁺ cells collected from the primary recipients. B, C Flow cytometry plots (left) and the percentage of GFP⁺ cells in PBMC (right, B, n = 5) and the percentages of GFP⁺ cells and MGs (GFP⁺Mac-1⁺Gr1⁺) in BM (right, C, n = 5) from recipients with secondary transplantation of AML cells. D Representative images of Giemsa-Wright staining (left) and frequencies of blast cells (right) for Fbxo22^+/+ and Fbxo22^−/− BM cells upon the second transplantation. Red and green arrows point to representative blast cells and differentiated cells, respectively. E, F Gross pathology (left, E) and relative weights (right, E) and hematoxylin–eosin staining (F) of the livers and spleens from the secondary recipients (n = 5). G, H Survival curves for recipient mice receiving Fbxo22^+/+ or Fbxo22^−/− MLL-AF9⁺ BM cells upon the second (G) and third transplantation (H) (n = 6). Error bars denote mean ± SD. Statistical significance was determined by two-tailed unpaired t test (A–E) or log-rank test (G, H), and the P values were shown. All animal experiments were repeated at least twice with similar results